Kirin Limited

KNBWY | OTC

Price Alert Chart Builder DCF Calculator

$20.11

+$1.08 (+5.68%)

At close: Nov 5, 2026, 3:58 PM ET

$20.11

$0.00 (0.00%)

After-hours: Nov 5, 2026, 4:01 PM ET

Overview Rating Statistics Financials Earnings Ownership Dividends Profile

+5.68%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 5, 2026

60.5

-0.2 pts

Fundamentals Strong

Market Sentiment Bullish

Moat Narrow

Sector Rank #41/298 (Top 14%)

Full Analysis

Key Statistics

Market Data

Market Cap $16.06B

1D Range

19.55 20.21

52W Range

14.41 20.21

Valuation (TTM)

PE 12.07

PB 1.82

EV/EBITDA 7.74

Valuation (NTM)

Forward PE 13.26

Forward PEG 0.72

Price Target $0.00

Cash Flow

FCF Yield 8.2%

SBC Adj. FCF Yield 8.2%

SBC Impact N/A

Margins

Gross Margin 48.4%

Operating Margin 11.4%

FCF Margin 7.8%

Growth (CAGR)

Revenue 3Y | 5Y 7.2% | 6.4%

Dil EPS 3Y | 5Y 31.2% | 26.6%

FCF 3Y | 5Y 92.7% | 9.5%

Returns

ROA 5.8%

ROE 15.3%

ROIC 7.8%

Financial Health

Net Debt

¥675.53B ($4.16B)

Current Ratio 1.48

Interest Coverage 14.03

Dividends

Div Yield 4.89%

Payout Ratio 0.4%

FCF Payout Ratio 30.4%

All Key Statistics

Loading financial charts...

Profile

Kirin Holdings Company, Limited, a diversified global conglomerate, was established in 1885 and maintains its headquarters in Tokyo, Japan. This entity operates across Japan and internationally, manuf...

Sector Consumer Defensive

Industry Beverages - Alcoholic

Employees 31,144

IPO Date Mar 17, 1980

Website www.kirinholdings.com

Fiscal Year n/a

Full Company Profile

Latest News

1 day ago · globenewswire.com

Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026

– Two oral presentations to feature first ziftomenib combination data with quizartinib in newly diagnosed and gilteritinib in relapsed/refractory NPM1/FLT3 co-mutated AML –

15 days ago · zacks.com

Kirin (KNBWY) is an Incredible Growth Stock: 3 Reasons Why

Kirin (KNBWY) could produce exceptional returns because of its solid growth attributes.

15 days ago · zacks.com

Are Investors Undervaluing Kirin (KNBWY) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

5 months ago · globenewswire.com

The XLH Network and Kyowa Kirin Launch the XLH Community Guidebook to Help People Navigate Lifelong Journey with XLH

New online resource brings together practical information, community perspectives, and expert guidance tailored to people with XLH across ages and life stages New online resource brings together practical information, community perspectives, and expert guidance tailored to people with XLH across ages and life stages

1 year ago · zacks.com

Should Value Investors Buy Kirin (KNBWY) Stock?

Earnings

Next Earnings

Nov 10, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞